🔎 Trials Near Me

Utama › Limfoma Sel B Besar Difus › North Carolina

Kajian klinikal Limfoma Sel B Besar Difus di North Carolina

20 kajian untuk Limfoma Sel B Besar Difus sedang mencari peserta di lokasi di North Carolina.

Bandar di North Carolina

Teks kajian rasmi (Bahasa Inggeris)

Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

  • Novant Health Cancer Institute- Hematology, Charlotte
  • Duke Blood Cancer Center, Durham
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT06500273

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

  • East Carolina University ( Site 0159), Greenville
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT06717347

A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma

  • Duke University Medical Center, Durham
  • East Carolina University, Greenville
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT06091865

A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

  • University of North Carolina Medical Center ( Site 0136), Chapel Hill
  • Novant Health Presbyterian Medical Center ( Site 0177), Charlotte
  • Novant Health Forsyth Medical Center ( Site 0206), Winston-Salem
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT06890884

A Study of ARC-02 in B-cell NHL

  • Levine Cancer Institute, Charlotte
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 26 Ogo 2026 · NCT07691606

Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

  • Atrium Health Wake Forest Baptist, Winston-Salem
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Ogo 2026 · NCT05826535

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

  • University of North Carolina at Chapel Hill/ University of North Carolina Medical Center, Chapel Hill
Mengambil pesertaFasa 1/2
Umur 13 hingga 90 · Semua jantina · Dikemas kini 6 Ogo 2026 · NCT06533579

Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU

  • Duke University Medical Center - Division of Hematologic Malignancies, Durham
Mengambil pesertaKajian pemerhatian
Umur 18 ke atas · Semua jantina · Dikemas kini 5 Ogo 2026 · NCT06116110

A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

  • Duke Cancer Institute, Durham
  • Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 4 Ogo 2026 · NCT07188558

DALY II USA/ MB-CART2019.1 for DLBCL

  • Duke University Medical Center - Division of Hematologic Malignancies, Durham
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 13 Jul 2026 · NCT04792489

Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

  • Wake Forest University Health Sciences, Winston-Salem
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 9 Jul 2026 · NCT06015880

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

  • Duke University Medical Center, Durham
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Jul 2026 · NCT05131022

Registry of Older Patients With Cancer

  • Seby B. Jones Cancer Center, Boone
  • Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
  • East Carolina University, Greenville
  • dan 4 lagi
Mengambil pesertaKajian pemerhatian
Umur 65 ke atas · Semua jantina · Dikemas kini 29 Jun 2026 · NCT01137825

Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.

  • Duke Univerisity, Durham
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 13 Feb 2026 · NCT04775745

Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

  • Carolinas Medical Center/Levine Cancer Institute, Charlotte
  • Atrium Health Cabarrus/LCI-Concord, Concord
  • Wake Forest University Health Sciences, Winston-Salem
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Feb 2026 · NCT05633615

Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer

  • Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
Mengambil pesertaKajian pemerhatian
Umur 18 hingga 120 · Semua jantina · Dikemas kini 27 Okt 2025 · NCT01137643

A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies

  • University of North Carolina, Chapel Hill
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Okt 2025 · NCT05780034

A Study of NX-1607 in Adults With Advanced Malignancies

  • University of North Carolina, Chapel Hill
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 9 Sep 2025 · NCT05107674

Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy

  • UNC Lineberger Comprehensive Cancer Center, Chapel Hill
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 26 Sep 2024 · NCT06238648

DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

  • Brody School of Medicine at East Carolina University, Greenville
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 7 Apr 2023 · NCT04920617

Daripada ClinicalTrials.gov, data diperoleh pada 4 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.